GSK Submits Respiratory Syncytial Virus Vaccine for Regulatory Review to Health Canada
Shots:
- Health Canada received a submission from GSK for RSV older adult vaccine candidates in adults aged ≥60yrs.
- The submission includes the results from the P-III trial (AReSVi-006) evaluating the efficacy of a single dose of GSK's adjuvanted RSVPreF3 older adult vaccine in adults aged ≥60yrs. in 25,000 patients against RSV-lower respiratory tract disease across 17 countries incl. Canada
- If the RSV older adult vaccine candidate is approved, it will be the first vaccine to protect adults aged ≥60yrs. from lower respiratory tract disease caused by RSV inf.
Ref: GSK | Image: GSK
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
